Categories: News

Financière de Tubize – Annual report 2023

FINANCIERE DE TUBIZE SA/NV

Allée de la Recherche 60, 1070 Brussels

Contact: investorrelations@financiere-tubize.be

Annual Report 2023

Regulated information
16 March 2024

The board of directors of Financière de Tubize has established the 2023 annual report. This report is available on the website www.financiere-tubize.be

  • Profit for the financial year: € 88.2 million (€ 85.2 million in 2022, +3,5%),
  • Increase of outstanding bank borrowings from € 47.8 million at 31 December 2022 to € 79.2 million at 31 December 2023,
  • Acquisition of 1,043,881 UCB shares, increasing the holding of the Company in UCB from 35.70% on 31 December 2022 to 36.24% on 31 December 2023.

If the general shareholders meeting of 26 April 2024 approves the 2023 annual accounts, including the proposed result appropriation, a gross dividend of € 0.97 (compared to €0.86 for financial year 2022, an increase of 12.8%) will be payable as from 3rd of May 2024 onwards at the offices, seats and branches of BNP Paribas Fortis, in exchange of coupon n° 19.

Ex-dividend          30 April 2024
Record date          2 May 2024
Payment date       3 May 2024

Staff

Recent Posts

AI/ML Innovations Closes Acquisition of Quantum Sciences Ltd.

Strategic Expansion into Cardio AI-Driven Healthcare SolutionsCollaboration to Enhance Patient-Centered Digital Healthcare TechnologiesWelcomes Key Industry…

3 hours ago

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

17 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

18 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

18 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

19 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

21 hours ago